134 related articles for article (PubMed ID: 38214494)
1. A case of anti-laminin γ1 (p200) pemphigoid developed after dipeptidyl peptidase-4 inhibitor administration.
Nakatani K; Noborio R; Nomura Y; Ueki Y; Kiyohara T; Hashimoto T
J Dermatol; 2024 Jun; 51(6):869-872. PubMed ID: 38214494
[TBL] [Abstract][Full Text] [Related]
2. Laboratory Diagnosis and Clinical Profile of Anti-p200 Pemphigoid.
Meijer JM; Diercks GF; Schmidt E; Pas HH; Jonkman MF
JAMA Dermatol; 2016 Aug; 152(8):897-904. PubMed ID: 27167149
[TBL] [Abstract][Full Text] [Related]
3. Dipeptidyl peptidase-4 inhibitor-associated bullous pemphigoid, likely triggered by scabies, in a hemodialysis patient with human leukocyte antigen-DQB1*03:01.
Hibi A; Kasahara Y; Ishihara Y; Hata K; Hosokawa N; Nakagawa T
CEN Case Rep; 2020 Aug; 9(3):189-194. PubMed ID: 31993957
[TBL] [Abstract][Full Text] [Related]
4. Symmetrical Skin Lesions on the Gluteal Region in a Patient with Anti-Laminin-332 Mucous Membrane Pemphigoid.
Maki N; Demitsu T; Nagato H; Okada O; Yoneda K; Hashimoto T; Hasunuma N; Osada I; Manabe M
Acta Dermatovenerol Croat; 2021 Jul; 29(2):105-107. PubMed ID: 34477077
[TBL] [Abstract][Full Text] [Related]
5. [Anti-p200 pemphigoid: Remission under mycophenolate mofetil (Cellcept®)].
Raffin D; Delaplace M; Roussel A; Estève E
Ann Dermatol Venereol; 2013 Dec; 140(12):784-7. PubMed ID: 24315224
[TBL] [Abstract][Full Text] [Related]
6. A Cross-Sectional Study Comparing the Prevalence of Bullous Pemphigoid Autoantibodies in 275 Cases of Type II Diabetes Mellitus Treated With or Without Dipeptidyl Peptidase-IV Inhibitors.
Izumi K; Nishie W; Beniko M; Shimizu H
Front Immunol; 2019; 10():1439. PubMed ID: 31297116
[No Abstract] [Full Text] [Related]
7. Anti-p200 pemphigoid.
Goletz S; Hashimoto T; Zillikens D; Schmidt E
J Am Acad Dermatol; 2014 Jul; 71(1):185-91. PubMed ID: 24767733
[TBL] [Abstract][Full Text] [Related]
8. Decrease in eosinophils infiltrating into the skin of patients with dipeptidyl peptidase-4 inhibitor-related bullous pemphigoid.
Chijiwa C; Takeoka S; Kamata M; Tateishi M; Fukaya S; Hayashi K; Fukuyasu A; Tanaka T; Ishikawa T; Ohnishi T; Watanabe S; Tada Y
J Dermatol; 2018 May; 45(5):596-599. PubMed ID: 29411416
[TBL] [Abstract][Full Text] [Related]
9. From anti-p200 pemphigoid to anti-laminin gamma1 pemphigoid.
Dainichi T; Koga H; Tsuji T; Ishii N; Ohyama B; Ueda A; Natsuaki Y; Karashima T; Nakama T; Yasumoto S; Zillikens D; Hashimoto T
J Dermatol; 2010 Mar; 37(3):231-8. PubMed ID: 20507386
[TBL] [Abstract][Full Text] [Related]
10. Dipeptidyl peptidase-4 inhibitor-associated anti-laminin-γ1 (p200) pemphigoid in a patient with psoriasis vulgaris.
Minakawa S; Matsuzaki Y; Hashimoto T; Ishii N; Nishie W; Kayaba H; Sawamura D
J Dermatol; 2020 Jan; 47(1):e25-e26. PubMed ID: 31646656
[No Abstract] [Full Text] [Related]
11. [Anti-p200 pemphigoid: a spectacular response to dapsone].
Munsch C; Prey S; Joly P; Meyer N; Lamant L; Livideanu C; Viraben R; Paul C
Ann Dermatol Venereol; 2011 Nov; 138(11):739-42. PubMed ID: 22078034
[TBL] [Abstract][Full Text] [Related]
12. Bullous pemphigoid positive for anti-BP180 and anti-laminin 5 antibodies in a patient with graft-vs-host disease.
Izumi R; Fujimoto M; Yazawa N; Nakashima H; Asashima N; Watanabe R; Kuwano Y; Kurokawa M; Hashimoto T; Tamaki K
J Am Acad Dermatol; 2007 May; 56(5 Suppl):S94-7. PubMed ID: 17434049
[TBL] [Abstract][Full Text] [Related]
13. [Anti-p200 pemphigoid].
Holtsche MM; Goletz S; Zillikens D
Hautarzt; 2019 Apr; 70(4):271-276. PubMed ID: 30868255
[TBL] [Abstract][Full Text] [Related]
14. Usefulness of immunofluorescence overlay antigen mapping in the identification of autoantigen in anti-p200 pemphigoid.
Kitayama S; Makino T; Hayashi M; Mizawa M; Ishii N; Hashimoto T; Shimizu T
J Dermatol; 2023 Sep; 50(9):1194-1198. PubMed ID: 37082790
[TBL] [Abstract][Full Text] [Related]
15. Pemphigoid with antibodies to laminin γ1, BP180 and BP230, associated with psoriasis vulgaris: successful disease control with cyclosporin.
Imanishi A; Tateishi C; Imanishi H; Sowa-Osako J; Koga H; Tsuruta D; Hashimoto T
J Dermatol; 2015 Apr; 42(4):394-7. PubMed ID: 25708520
[TBL] [Abstract][Full Text] [Related]
16. Pathogenicity of autoantibodies in anti-p200 pemphigoid.
Vafia K; Groth S; Beckmann T; Hirose M; Dworschak J; Recke A; Ludwig RJ; Hashimoto T; Zillikens D; Schmidt E
PLoS One; 2012; 7(7):e41769. PubMed ID: 22911854
[TBL] [Abstract][Full Text] [Related]
17. Dipeptidyl peptidase 4 inhibitor-associated mucous membrane pemphigoid.
Suezawa M; Dainichi T; Kaku Y; Izumi M; Kataoka K; Ishii N; Koga H; Izumi K; Nishie W
J Dermatol; 2021 Oct; 48(10):1584-1587. PubMed ID: 34265108
[TBL] [Abstract][Full Text] [Related]
18. IgA anti-p200 pemphigoid.
Wozniak K; Hashimoto T; Fukuda S; Ohyama B; Ishii N; Koga H; Dainichi T; Kowalewski C
Arch Dermatol; 2011 Nov; 147(11):1306-10. PubMed ID: 22106117
[TBL] [Abstract][Full Text] [Related]
19. Case of subepidermal autoimmune bullous disease with psoriasis vulgaris reacting to both BP180 C-terminal domain and laminin gamma-1.
Ishida S; Takahashi K; Kanaoka M; Okawa T; Tateishi C; Yasukochi A; Ishii N; Li X; Hashimoto T; Aihara M
J Dermatol; 2015 Apr; 42(4):391-3. PubMed ID: 25683229
[TBL] [Abstract][Full Text] [Related]
20. Anti-laminin gamma-1 pemphigoid.
Dainichi T; Kurono S; Ohyama B; Ishii N; Sanzen N; Hayashi M; Shimono C; Taniguchi Y; Koga H; Karashima T; Yasumoto S; Zillikens D; Sekiguchi K; Hashimoto T
Proc Natl Acad Sci U S A; 2009 Feb; 106(8):2800-5. PubMed ID: 19196964
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
